Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.5% – What’s Next?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) were down 5.5% during trading on Tuesday . The stock traded as low as $32.20 and last traded at $32.1190. Approximately 26,579 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 39,008 shares. The stock had previously closed at $34.00.

Analyst Ratings Changes

A number of research analysts recently weighed in on NBTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Guggenheim lifted their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Trading Up 1.8%

The business’s fifty day moving average is $25.90 and its 200-day moving average is $21.68.

Institutional Investors Weigh In On Nanobiotix

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Nanobiotix during the fourth quarter valued at $390,000. Royal Bank of Canada lifted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Nanobiotix during the 4th quarter worth $220,000. Finally, Optiver Holding B.V. purchased a new stake in Nanobiotix in the 3rd quarter worth about $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.